CN103588704B - 粘着斑激酶抑制剂 - Google Patents

粘着斑激酶抑制剂 Download PDF

Info

Publication number
CN103588704B
CN103588704B CN201310403215.3A CN201310403215A CN103588704B CN 103588704 B CN103588704 B CN 103588704B CN 201310403215 A CN201310403215 A CN 201310403215A CN 103588704 B CN103588704 B CN 103588704B
Authority
CN
China
Prior art keywords
trifluoromethyl
ylamino
pyridin
alkyl
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201310403215.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN103588704A (zh
Inventor
梁从新
马塞尔·凯尼格
何元君
帕尔·霍姆伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CN103588704A publication Critical patent/CN103588704A/zh
Application granted granted Critical
Publication of CN103588704B publication Critical patent/CN103588704B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201310403215.3A 2007-03-16 2008-03-10 粘着斑激酶抑制剂 Expired - Fee Related CN103588704B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US89537907P 2007-03-16 2007-03-16
US60/895,379 2007-03-16
US94663707P 2007-06-27 2007-06-27
US60/946,637 2007-06-27
US3002508P 2008-02-20 2008-02-20
US61/030,025 2008-02-20
CN200880015910A CN101679264A (zh) 2007-03-16 2008-03-10 粘着斑激酶抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN200880015910A Division CN101679264A (zh) 2007-03-16 2008-03-10 粘着斑激酶抑制剂

Publications (2)

Publication Number Publication Date
CN103588704A CN103588704A (zh) 2014-02-19
CN103588704B true CN103588704B (zh) 2016-09-14

Family

ID=39628767

Family Applications (2)

Application Number Title Priority Date Filing Date
CN200880015910A Pending CN101679264A (zh) 2007-03-16 2008-03-10 粘着斑激酶抑制剂
CN201310403215.3A Expired - Fee Related CN103588704B (zh) 2007-03-16 2008-03-10 粘着斑激酶抑制剂

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN200880015910A Pending CN101679264A (zh) 2007-03-16 2008-03-10 粘着斑激酶抑制剂

Country Status (10)

Country Link
US (2) US8501763B2 (enExample)
EP (2) EP2134689B1 (enExample)
JP (2) JP5569956B2 (enExample)
CN (2) CN101679264A (enExample)
CA (1) CA2681015C (enExample)
DK (1) DK2134689T3 (enExample)
ES (1) ES2485040T3 (enExample)
PL (1) PL2134689T3 (enExample)
TW (2) TW201618780A (enExample)
WO (1) WO2008115369A2 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2485040T3 (es) 2007-03-16 2014-08-12 The Scripps Research Institute Inhibidores de cinasa de adhesión focal
GB0719644D0 (en) 2007-10-05 2007-11-14 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB0803018D0 (en) 2008-02-19 2008-03-26 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
MX2010014057A (es) * 2008-06-17 2011-03-21 Astrazeneca Ab Compuestos de piridina.
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
KR20100067046A (ko) * 2008-12-10 2010-06-18 동화약품주식회사 신규한 ２，６―위치에 치환된 ３―니트로피리딘 유도체, 그의 제조방법 및 이를 포함하는 약학 조성물
WO2011019943A1 (en) * 2009-08-12 2011-02-17 Poniard Pharmaceuticals, Inc. Method of promoting apoptosis and inhibiting metastasis
JP5607241B2 (ja) 2010-05-21 2014-10-15 ケミリア・エービー 新規ピリミジン誘導体
EP2588081A4 (en) * 2010-06-29 2014-12-10 Verastem Inc ORAL FORMULATION OF CHINESE INHIBITORS
AU2011280031B2 (en) * 2010-06-30 2015-09-10 Verastem, Inc. Synthesis and use of Kinase inhibitors
DE102010034699A1 (de) 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
MX2013008654A (es) * 2011-01-26 2013-09-02 Glaxosmithkline Intellectual Property Ltd Combinaciones.
DK2675793T3 (en) 2011-02-17 2018-11-12 Cancer Therapeutics Crc Pty Ltd FAK INHIBITORS
WO2012110774A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
EP2688883B1 (en) 2011-03-24 2016-05-18 Noviga Research AB Pyrimidine derivatives
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
BR112014010938A2 (pt) 2011-11-09 2017-05-16 Cancer Res Tech Ltd compostos de 5-(piridin-2-il-amino)-pirazina-2-carbonitrila e seu uso terapêutico
PL2855448T3 (pl) 2012-05-15 2017-09-29 Cancer Research Technology Ltd 5-[[4-[[morfolino-2-ilo]metyloamino]-5-(trifluorometylo)-2-pirydylo]amino]pirazyno-2-karbonitryl i jego zastosowanie terapeutyczne
KR20150087400A (ko) 2012-11-20 2015-07-29 버텍스 파마슈티칼스 인코포레이티드 인돌아민 2,3-디옥시게나제의 억제제로서 유용한 화합물
CN105164114B (zh) * 2013-05-01 2018-03-23 豪夫迈·罗氏有限公司 C‑连接的杂环烷基取代的嘧啶类和它们的用途
WO2015035199A1 (en) * 2013-09-06 2015-03-12 Mayo Foundation For Medical Education And Research Neem compositions used for the treatment of cancer
US10106834B2 (en) 2013-10-09 2018-10-23 The General Hospital Corporation Methods of diagnosing and treating B cell acute lymphoblastic leukemia
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
CN114209841A (zh) 2015-06-29 2022-03-22 维瑞斯特姆股份有限公司 治疗组合物、组合和使用方法
EA034440B1 (ru) 2015-10-29 2020-02-07 Эффектор Терапьютикс, Инк. СОЕДИНЕНИЯ ПИРРОЛО-, ПИРАЗОЛО-, ИМИДАЗОПИРИМИДИНА И ПИРИДИНА, КОТОРЫЕ ИНГИБИРУЮТ Mnk1 И Mnk2
CA3002877A1 (en) 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
AU2016359438B2 (en) * 2015-11-26 2019-05-02 Novartis Ag Diamino pyridine derivatives
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
EP3582776B1 (en) 2017-02-14 2023-11-08 Effector Therapeutics, Inc. Piperidine-substituted mnk inhibitors and methods related thereto
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
JP2021517589A (ja) 2018-03-12 2021-07-26 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用
EP3856190A4 (en) * 2018-09-27 2022-09-21 Dana Farber Cancer Institute, Inc. DEGRADATION OF FAK OR FAK AND ALK BY CONJUGATION OF FAK AND ALK INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
KR20210102211A (ko) 2018-10-24 2021-08-19 이펙터 테라퓨틱스, 인크. Mnk 억제제의 결정질 형태
CN110724137B (zh) * 2019-11-13 2021-03-30 广东工业大学 一种噻吩类衍生物及其制备方法与应用
CN111233834B (zh) * 2020-03-09 2021-08-31 北京师范大学 一类靶向fak的化合物和其标记物、及它们的制备方法和应用
WO2021237121A1 (en) * 2020-05-21 2021-11-25 Gossamer Bio Services, Inc. Substituted pyridines
CN114181257B (zh) * 2020-09-14 2025-02-14 四川科伦博泰生物医药股份有限公司 吡啶类化合物，包含其的药物组合物，其制备方法及其用途
WO2022133046A2 (en) * 2020-12-16 2022-06-23 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
GB202113079D0 (en) * 2021-09-14 2021-10-27 Ucl Business Ltd New therapy
WO2023218245A1 (en) * 2022-05-13 2023-11-16 Voronoi Inc. Heteroaryl derivative compounds, and pharmaceutical composition comprising thereof
WO2024251270A1 (zh) * 2023-06-08 2024-12-12 希格生科（深圳）有限公司 含氮芳环化合物及其医药用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062233A2 (en) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
CN1406231A (zh) * 2000-03-01 2003-03-26 阿斯特拉曾尼卡有限公司 嘧啶化合物
WO2004002410A2 (en) * 2002-06-27 2004-01-08 Bristol-Myers Squibb Company 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors
WO2004011456A1 (en) * 2002-07-31 2004-02-05 Danter Wayne R Protein tyrosine kinase inhibitors
CN1697830A (zh) * 2002-03-15 2005-11-16 诺瓦提斯公司 嘧啶衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2007309427B2 (en) 2006-10-23 2013-02-28 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
KR101149295B1 (ko) 2006-12-08 2012-07-05 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물
RS53588B1 (sr) * 2006-12-08 2015-02-27 Irm Llc Jedinjenja i kompozicije kao inhibitori protein kinaza
ES2485040T3 (es) 2007-03-16 2014-08-12 The Scripps Research Institute Inhibidores de cinasa de adhesión focal
WO2009105498A1 (en) 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062233A2 (en) * 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
CN1406231A (zh) * 2000-03-01 2003-03-26 阿斯特拉曾尼卡有限公司 嘧啶化合物
CN1697830A (zh) * 2002-03-15 2005-11-16 诺瓦提斯公司 嘧啶衍生物
WO2004002410A2 (en) * 2002-06-27 2004-01-08 Bristol-Myers Squibb Company 2,4-disubstituted-pyridine n-oxides useful as hiv reverse transcriptase inhibitors
WO2004011456A1 (en) * 2002-07-31 2004-02-05 Danter Wayne R Protein tyrosine kinase inhibitors

Also Published As

Publication number Publication date
EP2134689B1 (en) 2014-04-23
JP5569956B2 (ja) 2014-08-13
TWI536991B (zh) 2016-06-11
JP2010521458A (ja) 2010-06-24
EP2727909A1 (en) 2014-05-07
CA2681015C (en) 2016-06-21
US9580439B2 (en) 2017-02-28
US20110046121A1 (en) 2011-02-24
US20130281443A1 (en) 2013-10-24
CN103588704A (zh) 2014-02-19
PL2134689T3 (pl) 2014-10-31
ES2485040T3 (es) 2014-08-12
EP2134689A2 (en) 2009-12-23
TW201618780A (zh) 2016-06-01
CA2681015A1 (en) 2008-09-25
WO2008115369A3 (en) 2008-11-13
WO2008115369A2 (en) 2008-09-25
DK2134689T3 (da) 2014-06-30
CN101679264A (zh) 2010-03-24
US8501763B2 (en) 2013-08-06
JP2014148542A (ja) 2014-08-21
TW200901996A (en) 2009-01-16

Similar Documents

Publication Publication Date Title
CN103588704B (zh) 粘着斑激酶抑制剂
JP2010521458A5 (enExample)
RU2615130C2 (ru) Гетероциклические соединения, используемые в качестве ингибиторов pdk1
CN106029661B (zh) 吡唑并[1,5‑a]吡啶衍生物及其使用方法
KR101614572B1 (ko) 디아미노 헤테로환 카르복사미드 화합물
AU2014367283B2 (en) Maleimide derivatives as modulators of WNT pathway
CN110049978A (zh) 作为选择性hdac1,2抑制剂的哌嗪衍生物
KR20070026357A (ko) 인돌 유도체, 및 키나제 억제제, 특히 ｉｋｋ2억제제로서의 그의 용도
WO2015187094A1 (en) Phthalimide derivatives as modulators of wnt pathway
HK1194380A (en) Inhibitors of focal adhesion kinase
HK1194380B (en) Inhibitors of focal adhesion kinase
HK1141521A (en) Inhibitors of focal adhesion kinase
WO2022253081A1 (zh) 氧化膦衍生物及其制备方法和应用
CN119816492A (zh) Trpv2通道阻断剂及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1194380

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1194380

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160914

Termination date: 20190310